MA45481A - Utilisation d'exosomes pour le traitement de maladies - Google Patents

Utilisation d'exosomes pour le traitement de maladies

Info

Publication number
MA45481A
MA45481A MA045481A MA45481A MA45481A MA 45481 A MA45481 A MA 45481A MA 045481 A MA045481 A MA 045481A MA 45481 A MA45481 A MA 45481A MA 45481 A MA45481 A MA 45481A
Authority
MA
Morocco
Prior art keywords
exosomes
diseases
treatment
Prior art date
Application number
MA045481A
Other languages
English (en)
Inventor
Raghu Kalluri
Sonia Melo
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MA45481A publication Critical patent/MA45481A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
    • A23C19/09—Other cheese preparations; Mixtures of cheese with other foodstuffs
    • A23C19/0904—Liquid cheese products, e.g. beverages, sauces
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L23/00—Soups; Sauces; Preparation or treatment thereof
    • A23L23/10—Soup concentrates, e.g. powders or cakes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
    • A23L25/10—Peanut butter
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/60—Salad dressings; Mayonnaise; Ketchup
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/212—Starch; Modified starch; Starch derivatives, e.g. esters or ethers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/231—Pectin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/238—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seeds, e.g. locust bean gum or guar gum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/25—Exudates, e.g. gum arabic, gum acacia, gum karaya or tragacanth
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/256—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seaweeds, e.g. alginates, agar or carrageenan
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/262—Cellulose; Derivatives thereof, e.g. ethers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/269—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/185—Vegetable proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L9/00—Puddings; Cream substitutes; Preparation or treatment thereof
    • A23L9/10—Puddings; Dry powder puddings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Pediatric Medicine (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
MA045481A 2015-06-10 2016-06-10 Utilisation d'exosomes pour le traitement de maladies MA45481A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562173838P 2015-06-10 2015-06-10

Publications (1)

Publication Number Publication Date
MA45481A true MA45481A (fr) 2018-04-18

Family

ID=56292904

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045481A MA45481A (fr) 2015-06-10 2016-06-10 Utilisation d'exosomes pour le traitement de maladies

Country Status (14)

Country Link
US (2) US20180177727A1 (fr)
EP (1) EP3307890A1 (fr)
JP (3) JP2018520125A (fr)
KR (1) KR102706532B1 (fr)
CN (2) CN113694075A (fr)
AU (1) AU2016275046B2 (fr)
BR (1) BR112017026467A2 (fr)
CA (1) CA2988585A1 (fr)
EA (1) EA201890006A1 (fr)
HK (1) HK1251257A1 (fr)
IL (1) IL256175B2 (fr)
MA (1) MA45481A (fr)
MX (1) MX2017015962A (fr)
WO (1) WO2016201323A1 (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US20180177727A1 (en) * 2015-06-10 2018-06-28 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
CN106727548B (zh) * 2016-12-23 2020-08-21 蒋培都 烷基吡啶类化合物在制备诱导细胞自噬药物的应用及方法
WO2018124835A1 (fr) * 2016-12-29 2018-07-05 한국과학기술연구원 Nouvel agent anticancéreux à base d'exosome
CN108066361A (zh) * 2017-01-23 2018-05-25 广州中科蓝华生物科技有限公司 一种外泌体，其制备方法及其在制备抗肿瘤的药物或者制剂中的用途
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
CN110520140A (zh) 2017-04-19 2019-11-29 菲格内有限责任公司 成纤维细胞衍生的外泌体刺激血管生成
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
KR20200044806A (ko) * 2017-07-28 2020-04-29 내셔널 유니버시티 오브 싱가포르 변형된 유령 세포를 포함하는 생물분자 복합체
TR201716062A2 (tr) * 2017-10-18 2019-05-21 Tuerkiye Bilimsel Ve Teknolojik Arastirma Kurumu Tuebitak Bi̇r eksozomal terapöti̇k taşiyici üreti̇m yöntemi̇ ve bu yönteme uygun bi̇r şeki̇lde elde edi̇len bi̇r eksozomal terapöti̇k taşiyici
KR102923958B1 (ko) * 2017-12-15 2026-02-06 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 엑소좀 관련 유전자 편집을 이용한 암 치료 방법 및 조성물
EP3505187A1 (fr) * 2017-12-27 2019-07-03 Tzu Chi University Administration d'un agent dans des cellules autophagiques et apoptotiques par des vésicules ayant une protéine exprimée sur leur surface
JP7253762B2 (ja) * 2017-12-27 2023-04-07 慈濟大學 タンパク質を表面に発現させた小胞によるオートファジー細胞およびアポトーシス細胞への薬剤送達
EP3752615B1 (fr) * 2018-02-12 2025-08-27 Lonza Sales AG Procédés et compositions pour la polarisation des macrophages
US20210000882A1 (en) * 2018-02-28 2021-01-07 Crown Scientific, LLC Production and use of extracellular vesicles
CN108486060B (zh) * 2018-03-12 2021-09-14 绍兴优铭生物科技有限公司 一种用于治疗肿瘤的外泌体及其制备方法和应用
CN112424219A (zh) * 2018-03-12 2021-02-26 得克萨斯州大学系统董事会 免疫外排体及其使用方法
WO2019178317A1 (fr) 2018-03-14 2019-09-19 Children's Medical Center Corporation Plate-forme d'évaluation de la transcytose de vésicules extracellulaires à travers des barrières endothéliales et ses utilisations
TW202003032A (zh) * 2018-03-23 2020-01-16 美商科迪亞克生物科學公司 包含ｓ ｔ ｉ ｎ ｇ 促效劑之胞外囊泡
JP7474702B2 (ja) 2018-03-28 2024-04-25 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム エキソソームから単離されたｄｎａにおけるエピジェネティック変化の同定法
JP7813099B2 (ja) * 2018-03-28 2026-02-12 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 治療用物質を標的送達するためのエキソソームの使用法
US11648260B2 (en) * 2018-03-29 2023-05-16 Technion Research And Development Foundation Limitted Vesicles comprising a PTEN inhibitor and uses of same
US20210024936A1 (en) * 2018-04-09 2021-01-28 Board Of Regents, The University Of Texas System Therapeutic targeting of oncogenes using exosomes
CA3097558A1 (fr) * 2018-04-19 2019-10-24 Board Of Regents, The University Of Texas System Modulation therapeutique de suppresseurs tumoraux a l'aide d'exosomes
CN108587998B (zh) * 2018-05-17 2021-05-18 浙江大学 一种外泌体、外泌体的制备方法及其在制备皮肤浅表性肿瘤的药物中的应用
CN108635372A (zh) * 2018-05-17 2018-10-12 广东芙金干细胞再生医学有限公司 一种人间充质干细胞源外泌体的生物制剂的制备方法
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
CN108866058B (zh) * 2018-07-12 2021-09-10 苏州吉玛基因股份有限公司 靶向KRAS的siRNA及其在制备胰腺癌治疗药物中的应用
CN108865976B (zh) * 2018-07-19 2022-06-28 复旦大学附属中山医院 一种离散汲取收集外泌体(exosome)的方法及试剂
CN108815187A (zh) * 2018-07-20 2018-11-16 深圳市第二人民医院 一种包含人关节液外泌体的制剂及其使用方法
WO2020028677A2 (fr) * 2018-08-01 2020-02-06 The Regents Of The University Of Colorado A Body Corporate Vésicules gectosomes sécrétés fusogènes thérapeutiques de conception programmable pour l'administration de macromolécules et la modification du génome
US12029821B2 (en) * 2018-08-10 2024-07-09 Omnispirant Limited Extracellular vesicles for inhalation
CN110960688A (zh) * 2018-09-30 2020-04-07 复旦大学 用于提高胰腺癌疗效的低毒仿生化纳米系统及制备方法
US20210395721A1 (en) 2018-10-24 2021-12-23 Codiak Biosciences, Inc. Methods to improve potency of electroporation
WO2020154500A1 (fr) 2019-01-23 2020-07-30 The Broad Institute, Inc. Protéines chargées supernégativement et utilisations associées
JP2022519583A (ja) * 2019-01-31 2022-03-24 ナショナル ユニヴァーシティー オブ シンガポール 神経変性疾患を検出する方法
CN113412422B (zh) 2019-01-31 2025-03-28 新加坡国立大学 传感器芯片及其方法
KR20210125530A (ko) * 2019-02-08 2021-10-18 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 노화 및 연령-관련 기관 기능부전과 연관된 질환을 치료하기 위한 텔로머라제-함유 엑소좀
MX2021011426A (es) 2019-03-19 2022-03-11 Broad Inst Inc Metodos y composiciones para editar secuencias de nucleótidos.
WO2020198626A1 (fr) * 2019-03-27 2020-10-01 University Of Georgia Research Foundation, Inc. Procédés de fabrication de vésicules ciblées, et compositions ainsi fabriquées
CN110004110A (zh) * 2019-04-09 2019-07-12 江苏省人民医院（南京医科大学第一附属医院） 一种肠道外泌体提取方法
WO2020214842A1 (fr) 2019-04-17 2020-10-22 The Broad Institute, Inc. Éditeurs de base d'adénine présentant des effets hors cible réduits
CA3137525A1 (fr) * 2019-04-23 2020-10-29 Children's Medical Center Corporation Utilisation d'inhibiteurs de la gtpase rab7 (rab7) pour augmenter la permeabilite de la barriere hemato-encephalique (bhe)
CN114258398A (zh) 2019-06-13 2022-03-29 总医院公司 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
WO2021026353A2 (fr) * 2019-08-06 2021-02-11 Ohio State Innovation Foundation Vésicules extracellulaires thérapeutiques
CA3147369A1 (fr) * 2019-08-14 2021-02-18 Dalia BURZYN Constructions vesicule extracellulaire-oligonucleotide antisens (aso) ciblant cebp/beta
CA3147680A1 (fr) * 2019-08-14 2021-02-18 Dalia BURZYN Constructions de vesicules extracellulaires - aso ciblant stat6
EP4013872A1 (fr) * 2019-08-14 2022-06-22 Codiak BioSciences, Inc. Vésicules extracellulaires à oligonucléotides antisens ciblant kras
US20220409741A1 (en) * 2019-09-02 2022-12-29 Kyungpook National University Industry-Academic Cooperation Foundation Composition for preventing or treating cancer, containing il-2 surface expression-extracellular vesicles as active ingredient
US20210154307A1 (en) 2019-11-07 2021-05-27 Northeastern University Cationic nanostructures for intra-cartilage delivery of therapeutics and contrast agents
CN112823811B (zh) * 2019-11-18 2022-07-29 深圳先进技术研究院 一种跨越血脑屏障和特异性靶向脑胶质瘤治疗药物的投递系统的制备方法
WO2021105392A1 (fr) * 2019-11-27 2021-06-03 Novaliq Gmbh Suspension comprenant une particule protéique suspendue dans un véhicule non aqueux
JP7674354B2 (ja) * 2019-12-05 2025-05-09 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 肝線維症および線維症に関連する他の疾患に対するエキソソームベースの療法
CN112972702A (zh) * 2019-12-17 2021-06-18 南京大学 用于治疗耐药菌感染的外泌体制剂
CA3168806A1 (fr) * 2020-01-22 2021-07-29 Agex Therapeutics, Inc. Exosomes therapeutiques et leur procede de production
CN111358957B (zh) * 2020-03-06 2024-03-26 西安组织工程与再生医学研究所 磁性纳米颗粒
CN114150066B (zh) * 2020-03-30 2022-06-03 中国医学科学院肿瘤医院 外泌体cda、hmgn1等在肺癌诊断中的应用
CA3169550A1 (fr) * 2020-04-07 2021-10-14 Chad PECOT Procedes et compositions utilisant l'interference par l'arn et des oligonucleotides antisens pour l'inhibition de kras
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
WO2022120366A1 (fr) * 2020-12-02 2022-06-09 Northwestern University Méthodes et compositions pour le traitement d'une infection à coronavirus, y compris au sars-cov 2
CN116981697A (zh) 2021-01-14 2023-10-31 森迪生物科学公司 可分泌有效载荷调节
CN113144222B (zh) * 2021-04-14 2023-05-23 台州学院 外泌体用于防止脑型疟疾发生的实验方法
IT202100021779A1 (it) * 2021-08-11 2023-02-11 Plasfer S R L Piastrine trasfettate con sirna e loro usi terapeutici
KR20240082391A (ko) * 2021-10-14 2024-06-10 론자 세일즈 아게 세포외 소포 생산을 위한 변형된 생산자 세포
CN115990261B (zh) * 2021-10-20 2024-01-05 光武惠文生物科技(北京)有限公司 外泌体冻干粉针剂或外泌体液体制剂的保护剂
US20250223584A2 (en) 2021-12-03 2025-07-10 The Broad Institute, Inc. Compositions and methods for efficient in vivo delivery
EP4526459A2 (fr) 2022-05-17 2025-03-26 Nvelop Therapeutics, Inc. Compositions et méthodes pour administration in vivo efficace
US20260053944A1 (en) * 2022-08-19 2026-02-26 Northeastern University Cationic peptide/protein-modified exosomes for applications in drug delivery
CN115895998A (zh) * 2022-11-16 2023-04-04 大连理工大学 一种不同植物组织来源的完整外泌体的分离方法
AU2024307229A1 (en) * 2023-06-28 2025-10-09 Exollence Co., Ltd. Pharmaceutical composition for preventing or treating cancer comprising sirna as active ingredient
CN117643575A (zh) * 2023-11-03 2024-03-05 中山大学 一种纳米材料及其制备方法和应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US20030064949A1 (en) 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US6391582B2 (en) 1998-08-14 2002-05-21 Rigel Pharmaceuticlas, Inc. Shuttle vectors
FR2785543B1 (fr) 1998-11-05 2003-02-28 Inst Nat Sante Rech Med Exosomes modifies et utilisations
GB9927320D0 (en) 1999-11-18 2000-01-12 Chiron Spa Exosome separation
US6812023B1 (en) 2000-04-27 2004-11-02 Anosys, Inc. Methods of producing membrane vesicles
JP2003535832A (ja) 2000-06-09 2003-12-02 ブリカス，テニ ポリヌクレオチドおよび薬物の標的化リポソームへのカプセル化
KR100909681B1 (ko) 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
CA2442670A1 (fr) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Traitement soignant ou retardant l'installation de la cecite
US20050159378A1 (en) 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
FR2827872A1 (fr) 2001-07-30 2003-01-31 Roussy Inst Gustave Vesicules membranaires de fluide biologique preleve in vivo, leur preparation et utilisation dans la stimulation d'une reponse immunitaire
US7704964B2 (en) 2001-08-17 2010-04-27 Exothera L.L.C. Methods and compounds for the targeting of protein to exosomes
AU2002359403A1 (en) 2001-11-15 2003-06-10 The Regents Of The University Of California METHODS AND COMPOSITIONS FOR REGULATION OF GENE EXPRESSION THROUGH MODULATION OF mRNA TURNOVER
US7405292B2 (en) 2002-02-19 2008-07-29 The Children's Hospital Of Philadelphia Cellular genes regulated by HIV-1 infection and methods of use thereof
US7803906B2 (en) 2002-03-22 2010-09-28 Gene Signal International Sa Composition comprising an angiogenesis related protein
KR100519384B1 (ko) 2002-08-13 2005-10-06 (주)누백스 유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도
US20040224893A1 (en) 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
US20080268429A1 (en) 2004-06-02 2008-10-30 Sourcepharm, Inc. Rna - Containing Microvesicles and Methods Therefor
GB0416120D0 (en) 2004-07-19 2004-08-18 Health Prot Agency Stable compositions containing OMV's
AU2006330922B2 (en) 2005-12-20 2012-07-26 Bristol-Myers Squibb Company Compositions and methods for producing a composition
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
CA2676113C (fr) 2007-07-25 2014-07-08 University Of Louisville Research Foundation, Inc. Micro arn associe a l'exosome en tant que marqueur de diagnostic
JP5769417B2 (ja) 2007-08-16 2015-08-26 ザ ロイヤル インスティチューション フォー ザ アドバンスメント オブ ラーニング／マギル ユニバーシティ 腫瘍細胞由来微小胞
CN105734128B (zh) 2008-02-01 2021-05-18 总医院有限公司 微泡在医学疾病和病况的诊断、预后以及治疗中的用途
EP2260109A4 (fr) 2008-02-28 2011-06-08 Univ Ohio State Res Found Procédés et compositions à base de micro-arn permettant de diagnostiquer, de pronostiquer et de traiter des troubles liés à la prostate
EP2294196A1 (fr) 2008-06-06 2011-03-16 Centre National de la Recherche Scientifique - CNRS Utilisation du système endolysosomal et de vésicules sécrétées (de type exosome) dans des traitements et des diagnostics basés sur des petits arn et l étude expérimentale de petits arn
CN107254538A (zh) 2008-11-12 2017-10-17 卡里斯生命科学瑞士控股有限责任公司 使用外来体来确定表现型的方法和系统
WO2013022995A2 (fr) 2011-08-08 2013-02-14 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Compositions de biomarqueurs et procédés
DK2419144T3 (da) 2009-04-17 2019-10-21 Univ Oxford Innovation Ltd Sammensætning til levering af genetisk materiale
WO2011002239A2 (fr) 2009-07-01 2011-01-06 주식회사이언메딕스 Microvésicules dérivées de cellules mammaliennes nucléées et utilisation de celles-ci
WO2011097480A1 (fr) * 2010-02-05 2011-08-11 University Of Louisville Research Foundation, Inc. Compositions exosomales et procédés pour le traitement de maladies
WO2011126010A1 (fr) * 2010-04-06 2011-10-13 三菱化学株式会社 Peptide pénétrant dans les cellules spécifique aux cellules cancéreuses et son utilisation
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
JP2013524811A (ja) 2010-04-20 2013-06-20 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド ナノザイム、ナノザイムの製造方法、およびナノザイムの使用方法
CN101869715A (zh) 2010-05-26 2010-10-27 江苏命码生物科技有限公司 载有干扰核糖核酸的细胞微粒子、其制备方法及其应用
CN102858375B (zh) 2010-05-26 2016-08-10 江苏命码生物科技有限公司 载有干扰核糖核酸的细胞微粒子、其制备方法及其应用
WO2011147175A1 (fr) 2010-05-26 2011-12-01 Zhang Chenyu Préparation de complexes microvésicule-sirna et utilisation desdits complexes dans le traitement du sida
EP2603592A2 (fr) 2010-08-13 2013-06-19 The University Court of the University of Glasgow Utilisations thérapeutiques de microvésicules et de microarn associés
AU2011316477A1 (en) 2010-10-11 2013-05-02 Medsaic Pty Ltd Assay for disease detection
US20120196285A1 (en) 2011-01-31 2012-08-02 Esoterix Genetic Laboratories, Llc Methods for Enriching Microparticles or Nucleic Acids Using Binding Molecules
CA2829586C (fr) 2011-03-11 2021-03-02 Children's Medical Center Corporation Procedes et compositions associes aux exosomes de cellules souches mesenchymateuses
WO2012131733A2 (fr) 2011-03-31 2012-10-04 Godavari Biorefineries Limited Compositions de milieu, procédé d'initiation et d'enrichissement de cultures de cellules souches et/ou de cellules de type cellules souches cancéreuses
JP6100762B2 (ja) * 2011-06-02 2017-03-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 膜で被包されたナノ粒子および使用方法
GB201121070D0 (en) * 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
US9777042B2 (en) 2011-12-15 2017-10-03 Morehouse School Of Medicine Method of purifying HIV/SIV Nef from exosomal fusion proteins
WO2013138427A1 (fr) 2012-03-16 2013-09-19 The General Hospital Corporation Administration de molécules thérapeutiques médiée par des microvésicules
US20130273544A1 (en) 2012-04-17 2013-10-17 Life Technologies Corporation Methods and compositions for exosome isolation
US9076953B2 (en) * 2012-05-09 2015-07-07 Qualcomm Incorporated Spin transistors employing a piezoelectric layer and related memory, memory systems, and methods
AR091004A1 (es) * 2012-05-09 2014-12-30 Gradalis Inc Arn en horquilla corta bifuncional (bi-arnhc) especifico de mutaciones de nucleotidos individuales en k-ras
HK1209021A1 (en) * 2012-06-07 2016-03-24 President And Fellows Of Harvard College Nanotherapeutics for drug targeting
JP6391582B2 (ja) 2012-11-13 2018-09-19 コディアック バイオサイエンシズ インコーポレイテッド 治療剤の送達方法
CA2892490A1 (fr) 2012-11-26 2014-05-30 Caris Science, Inc. Compositions de biomarqueur et procedes
CN105658796B (zh) 2012-12-12 2021-10-26 布罗德研究所有限公司 用于序列操纵的crispr-cas组分系统、方法以及组合物
BR112015023275B1 (pt) 2013-03-15 2022-06-21 Board Of Regents, The University Of Texas System Método in vitro de detecção de biomarcador de câncer
JP6137894B2 (ja) * 2013-03-22 2017-05-31 国立大学法人京都大学 リポソーム−エキソソームハイブリッドベシクル及びその調製法
EP2983721B2 (fr) * 2013-04-12 2021-01-20 Evox Therapeutics Limited Vésicules d'administration thérapeutiques
KR20150043937A (ko) 2013-10-15 2015-04-23 삼성전자주식회사 개체의 간암 진단용 조성물, 개체의 간암 진단하는 방법 및 개체의 간암 진단에 필요한 정보를 얻는 방법
WO2015085096A1 (fr) 2013-12-04 2015-06-11 Board Of Regents, The University Of Texas System Analyse d'adn génomique, d'arn et de protéines dans des exosomes pour le diagnostic et la thérapie
JP2017501149A (ja) 2013-12-12 2017-01-12 ザ・ブロード・インスティテュート・インコーポレイテッド 粒子送達構成成分を用いた障害及び疾患の標的化のためのｃｒｉｓｐｒ−ｃａｓ系及び組成物の送達、使用及び治療適用
DK3204022T3 (da) 2014-10-09 2021-03-08 Celularity Inc Placenta-afledte adhærente celle-exosomer og anvendelser deraf
US20160113966A1 (en) 2014-10-27 2016-04-28 Hans Klingemann Composition and methods of culture supernatant of khyg-1 cells
WO2016077639A2 (fr) 2014-11-12 2016-05-19 VL27, Inc. Thérapies nanovésiculaires
US20180177727A1 (en) 2015-06-10 2018-06-28 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
TWI781915B (zh) 2015-10-30 2022-11-01 財團法人國家衛生研究院 用於疫苗製備之於無血清、化學性界定培養基中之mdck懸浮細胞株
EP3430024A4 (fr) 2016-03-15 2019-11-13 Codiak BioSciences, Inc. Vésicules membranaires thérapeutiques
EP3500244A4 (fr) 2016-08-22 2020-05-13 Codiak BioSciences, Inc. Procédés de suppression de l'administration d'exosomes vers le foie et la rate
AU2017335084B2 (en) * 2016-09-30 2023-06-29 Ilias Biologics Inc. Compositions containing protein loaded exosome and methods for preparing and delivering the same

Also Published As

Publication number Publication date
IL256175B2 (en) 2024-10-01
EA201890006A1 (ru) 2018-05-31
IL256175A (en) 2018-02-28
HK1251257A1 (zh) 2019-01-25
US10959952B2 (en) 2021-03-30
KR102706532B1 (ko) 2024-09-19
KR20180017119A (ko) 2018-02-20
MX2017015962A (es) 2018-07-06
IL256175B1 (en) 2024-06-01
EP3307890A1 (fr) 2018-04-18
AU2016275046A1 (en) 2018-01-04
US20180177727A1 (en) 2018-06-28
JP2024023853A (ja) 2024-02-21
AU2016275046B2 (en) 2022-07-28
BR112017026467A2 (pt) 2018-09-11
JP2018520125A (ja) 2018-07-26
US20190117570A1 (en) 2019-04-25
CN107980004A (zh) 2018-05-01
WO2016201323A1 (fr) 2016-12-15
JP7620968B2 (ja) 2025-01-24
NZ738149A (en) 2024-02-23
CA2988585A1 (fr) 2016-12-15
JP2021107463A (ja) 2021-07-29
CN113694075A (zh) 2021-11-26

Similar Documents

Publication Publication Date Title
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
EP3370703A4 (fr) Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
EP3504187A4 (fr) Utilisation de la pridopidine pour le traitement du déclin fonctionnel
MA45192A (fr) Traitement d'association
ME03314B (fr) Thérapie basée sur l'arnm pour le traitement des maladies oculaires
EP3503890A4 (fr) Utilisation de la pridopidine pour le traitement des dystonies
EP3621973A4 (fr) Composés pour la prévention et le traitement de maladies et leur utilisation
EP3288592A4 (fr) Utilisation de cannabidiol pour le traitement de spasmes infantiles
MA45089A (fr) Utilisation d'indazoles 2-substitués pour le traitement et la prophylaxie de maladies auto-immunes
MA41449A (fr) Polythérapies pour le traitement de cancers
EP3380200A4 (fr) Compositions pour le traitement des cheveux
MA42999A (fr) Polythérapie pour le traitement de malignités
EP3512517A4 (fr) Utilisation de pridopidine pour le traitement de l'anxiété et de la dépression
EP3630196A4 (fr) Polythérapies pour le traitement de cancers
EP3380063A4 (fr) Compositions pour le traitement des cheveux
EP3344325A4 (fr) Administration locale de médicaments pour le traitement de l'asthme
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
EP3512506A4 (fr) Utilisation de la pridopidine pour le traitement du syndrome de rett
EP3347032A4 (fr) Traitement de l'ascite
EP3848022C0 (fr) Agent thérapeutique pour utilisation dans le traitement d'infections
EP3413898A4 (fr) Utilisation de tréhalose pour le traitement de maladies neurologiques